Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Future Medical Device Companies -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (80)	10/5/2007 10:10:45 AM
From: semi_infinite	Respond to of 136

>>>When asked if they had any competitor for the space he said no.<<< I don't watch Cramer. Apparently it was the CEO Fred Moll. It's amazing that he would say that. He has said some things in presentations and conference calls that made you wonder about his honesty but this one would take the cake. I need to go find the transcript myself because I have a hard time believing he would say that on public TV. Apparently, Cramer's thestreet.com had written article(s) about HNSN way before the IPO. It's almost as if they are part of the road show for the IPO so perhaps a secondary is coming now. By the way the non-competitor will have around 100 installations by year end. They were at 77 as of mid-year. HNSN? Maybe a tenth of that? and they don't have to deal with hospital remodeling/construction schedules. HNSN system ought to be flying off the shelves if you believe Fred Moll.

To: IRWIN JAMES FRANKEL who wrote (80)	10/5/2007 10:22:00 AM
From: semi_infinite	Respond to of 136

I just noticed you live in St. Louis. If you talk to management, please pass on my curiosity about their seeming lack of IR savvy and why their non-competitor is painting the PR channels with fluff. I know most big institutions aren't fooled by the HNSN fluff. Public perception, however true or false, affects market cap and financial matters.

To: IRWIN JAMES FRANKEL who wrote (80)	10/5/2007 11:21:08 AM
From: semi_infinite	Read Replies (1) \| Respond to of 136

I just watched the video replay on CNBC. He did acknowledge that he has competition in the electrophysiology space, which would be STXS. What he referred to as "no competition" is the structural heart disease space done through blood vessel access. I would agree with that narrow definition. ISRG does structural heart repairs but access is from outside of the blood vessels and heart. Corindus is also doing robotics work through blood vessels but they may be not be targeting structural heart disease at first. Washington U. in DC is heading the clinical tests there. STXS may and Corindus will target structural heart disease in the future I expect. There is no barrier to entry for them.